Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
FORT LAUDERDALE, Fla., May 21 /PRNewswire/ -- Newbridge Securities Corporation today announced the quarterly rebalancing and reconstitution of its Newbridge Nanotechnology Index (NYSEArca:...
LONDON, Oct. 4 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) today announces positive results of a Phase III clinical trial for Lodotra(TM), a new, modified-release tablet...
LONDON, Sept. 22 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) announces today that as part of the Company's ongoing initiatives to increase operational efficiency the...
Euro 15 million upfront and Euro 70 million in milestones Double Digit Royalties LONDON, Sept. 6 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) announces today that it has...
LONDON, Sept. 5 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE:Nasdaq:LSE:SKYE) announces today that the Company will issue its interim results for the six months ended 30 June 2006 to the...
LONDON, June 28 /PRNewswire-FirstCall/ -- The Annual General Meeting of SkyePharma plc (LSE:SKPLSE:Nasdaq:LSE:SKYE) was held in London today. All resolutions were passed, with the minimum...
LONDON, May 17 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces the appointment of Dr Ken Cunningham, Chief Operating Officer, as a Director of the Company. It was...
LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) and Kos Pharmaceuticals, Inc. (Nasdaq: KOSP, "Kos") will host a joint teleconference later today to discuss the US...
LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces today that it has entered into an agreement with Kos Pharmaceuticals, Inc. (NASDAQ:KOSP) ("Kos") to...
Innovative Single Epidural Injection 48 Hours of Post-Surgical Pain Relief LONDON, April 28 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE:Nasdaq:LSE:SKYE)) announces today that the UK...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
